Advertisement
Advertisement
FATE
Fate Therapeutics, Inc.
2.48
USDSponsored
-0.12
-4.42%
Aug 06, 11:56 UTC -4
Open
FATE Earnings Reports
Positive Surprise Ratio
FATE beat 24 of 42 last estimates.
57%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$978.18K
/-$0.27
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
-43.82%
/--
Fate Therapeutics, Inc. earnings per share and revenue
On Aug 05, 2026, FATE reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.27 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.39 million, with a --% difference.
Looking ahead to Q3 26, 13 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 978.18 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunocore Holdings plc - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
-$0.02
Surprise
-356.41%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
Lexicon Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.06
Surprise
-17.19%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
InflaRx N.V. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.09
Surprise
-60.12%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Ligand Pharmaceuticals Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.90
Actual
$2.37
Surprise
+24.56%
Tarsus Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.43
Surprise
-101.03%
FAQ
What were Fate Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Fate Therapeutics, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Fate Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Fate Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Fate Therapeutics, Inc.'s next earnings report?
Based on 13
analysts, Fate Therapeutics, Inc. is expected to report EPS of -$0.27 and revenue of $978.18K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement